198 related articles for article (PubMed ID: 31768697)
61. Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab.
Park S; Jung JA; Ju S; Lim HS
Front Pharmacol; 2023; 14():1288308. PubMed ID: 38293674
[No Abstract] [Full Text] [Related]
62. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer.
Zhang J; Cai J; Bello A; Roy A; Sheng J
J Clin Pharmacol; 2019 Oct; 59(10):1415-1424. PubMed ID: 31115908
[TBL] [Abstract][Full Text] [Related]
63. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
[TBL] [Abstract][Full Text] [Related]
64. Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat.
Zhao YY; Wang N; Liu WH; Tao WJ; Liu LL; Shen ZD
PLoS One; 2016; 11(3):e0151874. PubMed ID: 26987122
[TBL] [Abstract][Full Text] [Related]
65. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
66. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.
Hirsh V
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S62-70. PubMed ID: 21885001
[TBL] [Abstract][Full Text] [Related]
67. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
[TBL] [Abstract][Full Text] [Related]
68. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S
Clin Lung Cancer; 2017 Jan; 18(1):50-59. PubMed ID: 27856142
[TBL] [Abstract][Full Text] [Related]
69. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Ikeda S; Kato T; Ogura T; Sekine A; Oda T; Masuda N; Igawa S; Katono K; Otani S; Yamada K; Saito H; Kondo T; Hosomi Y; Nakahara Y; Nishikawa M; Utumi K; Misumi Y; Yamanaka T; Sakamaki K; Okamoto H
BMC Cancer; 2018 Mar; 18(1):241. PubMed ID: 29499653
[TBL] [Abstract][Full Text] [Related]
70. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C
Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
[TBL] [Abstract][Full Text] [Related]
71. PF-05280014: A Trastuzumab Biosimilar.
Paik J
BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
[TBL] [Abstract][Full Text] [Related]
72. Comparison of Efficacy and Safety of a Bevacizumab Biosimilar, in Combination with Chemotherapies, in Nonresectable Metastatic Colorectal Cancer and in Advanced Nonsquamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.
Kasliwal S; K R; Reddy P; Maharaj N; M G; Adhav A; Harsh K; Madnoorkar N; Diwan A; Gupta M; Patel G; J SB; Dvorkin MV
South Asian J Cancer; 2024 Jan; 13(1):66-76. PubMed ID: 38721097
[TBL] [Abstract][Full Text] [Related]
73. Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung Cancer.
Tong X; Xu H; Carlile DJ; Tomkinson H; Al-Huniti N; Zhou D
J Clin Pharmacol; 2019 Jan; 59(1):112-122. PubMed ID: 30102413
[TBL] [Abstract][Full Text] [Related]
74. Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups.
Yabuuchi H; Kawanami S; Iwama E; Okamoto I; Kamitani T; Sagiyama K; Yamasaki Y; Honda H
Radiology; 2018 Feb; 286(2):685-695. PubMed ID: 29059037
[TBL] [Abstract][Full Text] [Related]
75. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
Cortot AB; Audigier-Valette C; Molinier O; Le Moulec S; Barlesi F; Zalcman G; Dumont P; Pouessel D; Poulet C; Fontaine-Delaruelle C; Hiret S; Dixmier A; Renault PA; Becht C; Raffy O; Dayen C; Mazieres J; Pichon E; Langlais A; Morin F; Moro-Sibilot D; Besse B
Eur J Cancer; 2020 May; 131():27-36. PubMed ID: 32276179
[TBL] [Abstract][Full Text] [Related]
76. A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
Yamada K; Ichiki M; Takahashi K; Hisamatsu Y; Takeoka H; Azuma K; Shukuya T; Nishikawa K; Tokito T; Ishii H; Hoshino T
Cancer Chemother Pharmacol; 2016 Sep; 78(3):501-7. PubMed ID: 27402398
[TBL] [Abstract][Full Text] [Related]
77. Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.
Kato T; Seto T; Nishio M; Goto K; Yamamoto N; Okamoto I; Tao L; Yu W; Khaznadar T; Tajima K; Shibata M; Seki A; Yamamoto N
Drug Saf; 2018 Feb; 41(2):229-237. PubMed ID: 29043496
[TBL] [Abstract][Full Text] [Related]
78. [Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer].
Zheng X; Wang H; Zhang G; Yan X; Ma Z
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):513-518. PubMed ID: 30037370
[TBL] [Abstract][Full Text] [Related]
79. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study.
Park W; Lee SJ; Yun J; Yoo DH
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S25-31. PubMed ID: 26395834
[TBL] [Abstract][Full Text] [Related]
80. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]